ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1410	National Cancer Institute	Html	en	Endometrial Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing endometrial cancer and about research aimed at the prevention of this disease.	Surgical Adjuvant Breast 0.47836 Obstet Gynecol 0.483376 World Cancer Research 0.452806 endometrial carcinoma 0.52954 Engl J Med 0.456388 American Cancer Society 0.497798 Br J Cancer 0.455416 case-control study 0.441437 Int J Cancer 0.478131 early-stage breast cancer 0.461817 intentional weight loss 0.529248 breast cancer treatment 0.473891 breast cancer patients 0.472714 body mass index 0.470175 endometrial cases 0.529694 Cancer Causes Control 0.452081 Natl Cancer Inst 0.529481 lower endometrial cancer 0.563354 postmenopausal endometrial cancer 0.554715 modifiable risk factor 0.44186 endometrial cancer 0.948645 invasive breast cancer 0.472622 Cancer Treat Rep 0.454232 et al. 0.498732	early breast cancer 0.472532 tamoxifen-treated breast cancer 0.462067 nonpolyposis colorectal cancer 0.457467 endometrial cancer cases 0.601622 polycystic ovarian syndrome 0.445837 Cancer Epidemiol Biomarkers 0.47249 endometrial cancer risk 0.82277 Cancer Facts 0.44862 PUBMED Abstract 0.515106 Nutr Cancer 0.444116 widespread endometrial cancer 0.555715 Epidemiol Biomarkers Prev 0.442397 endometrial cancer incidence 0.612962 Breast Cancer Prevention 0.475561 African American women 0.440785 invasive gynecologic cancer 0.464853 postmenopausal women 0.497969 Abstract 0.52778 breast cancer 0.526041 adjuvant tamoxifen 0.441172 physical activity 0.445711 Breast Cancer Study 0.467445 breast cancer incidence 0.479289 National Surgical Adjuvant 0.475167	CLICK HERE
1501	National Cancer Institute	Html	en	Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood Hodgkin lymphoma.	nodular sclerosis hodgkin 0.365708 refractory pediatric Hodgkin 0.351319 refractory Hodgkin 0.416042 early Hodgkin lymphoma 0.394054 Hodgkin lymphoma cases 0.403293 Hodgkin disease-added value 0.362383 early-stage hodgkin lymphoma 0.391985 lymphocyte-predominant hodgkin 0.393688 Radiat Oncol Biol 0.45608 risk Hodgkin lymphoma 0.399452 favorable-risk Hodgkin lymphoma 0.388818 Hodgkin lymphoma histology 0.402552 pediatric hodgkin lymphoma 0.479624 German-Austrian Pediatric Hodgkin 0.419443 classic Hodgkin lymphoma 0.417403 pediatric Hodgkin disease 0.379402 high-risk Hodgkin lymphoma 0.432447 Hodgkin Study Group 0.371284 sclerosis Hodgkin lymphoma 0.410888 newly diagnosed Hodgkin 0.350548 Hodgkin lymphoma treatment 0.38529 childhood hodgkin lymphoma 0.384013 familial classical Hodgkin 0.365775 lymphocyte-predominant Hodgkin lymphoma-experience 0.349402 childhood hodgkin 0.486255	cancer survivor study 0.348591 et al. 0.539517 lymphocyte-rich classical Hodgkin 0.347809 pediatric hodgkin 0.578037 intermediate-risk hodgkin lymphoma 0.423631 advanced Hodgkin lymphoma 0.416897 refractory Hodgkin lymphoma 0.395506 PUBMED Abstract 0.412711 unfavorable pediatric Hodgkin 0.351719 Hodgkin lymphoma subtype 0.402744 Lymphocyte-predominant Hodgkin lymphoma 0.388987 advanced-stage Hodgkin 0.357413 lymphocyte predominant Hodgkin 0.374597 Abstract 0.561102 Clin Oncol 0.905331 Hodgkin Lymphoma Group 0.412086 classical Hodgkin lymphoma 0.427321 Oncol Biol Phys 0.463188 Hodgkin disease 0.410937 childhood cancer survivor 0.348315 unfavorable childhood Hodgkin 0.356068 hodgkin lymphoma 0.82441 recurrent Hodgkin lymphoma 0.392381 predominant Hodgkin lymphoma 0.394303	CLICK HERE
1513	National Cancer Institute	Html	en	Pancreatic Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of pancreatic cancer.	pancreatic carcinoma E6201 0.398831 unresectable pancreatic carcinoma 0.359985 pancreatic malignancy 0.311753 Engl J Med 0.337007 Ann Surg 0.317423 German CONKO-study group 0.318318 phase iii trial 0.413157 pancreatic tumors 0.328586 der Schelling GP 0.325496 randomized phase 0.350612 advanced pancreatic adenocarcinoma 0.470438 randomized trial 0.376847 patients 0.470655 investigational new drug 0.321651 Cooperative Oncology Group 0.454021 van der Schelling 0.325555 Moore MJ 0.343635 fixed-dose rate infusion 0.313379 pancreatic carcinoma 0.542646 Ann Oncol 0.304631 et al. 0.690156 Best supportive care 0.315629 study 0.356854 Expandable metal stents 0.329142	phase ii trial 0.320548 Hammel et al. 0.336299 Oncology Group study 0.328761 Clinical Trials Group 0.319844 gemcitabine-based induction chemotherapy 0.328647 National Cancer Institute 0.337583 den Bosch RP 0.325608 advanced unresectable pancreatic 0.366836 metastatic pancreatic cancer 0.353118 advanced pancreatic cancer 0.926655 advanced pancreatic carcinoma 0.404683 unresectable periampullary adenocarcinoma 0.332936 first-line therapy 0.306838 van den Bosch 0.324595 refractory pancreatic cancer 0.407704 advanced pancreas cancer 0.35576 Abstract 0.559395 Clin Oncol 0.91428 unresectable pancreatic cancer 0.410252 Canada Clinical Trials 0.318756 Eastern Cooperative Oncology 0.46104 drug treatment program 0.320206 gemcitabine 0.380059 active chemotherapy regimens 0.332336	CLICK HERE
1694	National Cancer Institute	Html	en	Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ®)–Patient Version	Childhood central nervous system (CNS) germ cell tumors form from germ cells (a type of cell that forms as a fetus develops and later becomes sperm in the testicles or eggs in the ovaries). Learn about the signs, tests to diagnose, and treatment of pediatric germ cell tumors in the brain in this expert-reviewed summary.	tumor marker levels 0.3628 cancer treatment 0.421684 Cell Tumors Treatment 0.421872 tumor marker 0.418943 blood tumor marker 0.368072 tumor marker tests 0.401497 germ cell tumor 0.574325 chemotherapy 0.377281 following PDQ summaries 0.365055 PDQ cancer information 0.426073 clinical trials 0.64034 Pediatric Treatment Editorial 0.365107 cancer information summary 0.398144 clinical trial 0.507274 childhood cns 0.519486 tumor markers 0.382879 CNS germ cell 0.581589 Extracranial Germ Cell 0.410121 different types 0.371541 NCI PDQ cancer 0.369493 radiation therapy 0.586685 Treatment Editorial Board 0.36802 Cord Tumors Treatment 0.393052 late effects 0.370411 treatment 0.581174	cancer cells 0.438925 treatment clinical trial 0.368062 PDQ Pediatric Treatment 0.363419 nervous system germ 0.412082 treatment clinical trials 0.389618 National Cancer Institute 0.397655 diagnose childhood CNS 0.382168 spinal cord 0.499499 tumor cells 0.386305 Germ cells tumors 0.441556 new treatment 0.423148 high tumor marker 0.363373 childhood cancer information 0.366666 external radiation therapy 0.366121 brain 0.390174 PDQ summary 0.396735 germ cell tumors 0.941151 cells 0.445231 cancer clinical trials 0.367524 stem cell rescue 0.36994 cancer 0.582086 standard treatment 0.367712 tumor marker level 0.399336 spinal cord tumors 0.390737	CLICK HERE
2108	National Cancer Institute	Html	es	Prevención del cáncer de esófago (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre los factores que pueden influir en el riesgo de cáncer de esófago y sobre la investigación dirigida a la prevención de esta enfermedad.	Engel LS 0.373609 Lindgren A 0.36811 upper gastrointestinal tract 0.346284 Cancer Research Fund 0.36332 double-blind intervention study 0.424218 Lagergren J 0.644302 Overholt BF 0.373783 American Cancer Society 0.556588 gastroesophageal reflux 0.530195 pooled analysis from 0.437305 Spechler SJ 0.373642 Kerlikowske K 0.370938 Symptomatic gastroesophageal reflux 0.441142 Instituto Nacional 0.401102 adenocarcinoma after antireflux 0.427487 Krewski D 0.370088 Sharma P 0.368176 Bergström R 0.435333 Chow WH 0.372718 with dysplasia 0.373025 Estados Unidos 0.417008 Natl Cancer Inst 0.801603 multi-site case-control study 0.44183 PDQ Prevención 0.356958 esophageal adenocarcinoma 0.994739	intestinal metaplasia 0.38046 Goyal RK 0.374621 Population attributable risks 0.444629 Siemiatycki J 0.370746 SEER Cancer Statistics 0.366598 Murray LJ 0.372685 Corley DA 0.666943 Muñoz N 0.361794 Cancer Facts 0.35503 gastric cancers 0.376055 cigarette smoking 0.377492 Norman Barrett 0.429462 Bang LJ 0.364677 National Cancer Institute 0.444849 Cancer Research 0.391943 gastric carcinoma 0.350615 Verma R 0.369649 Esophageal Adenocarcinoma Consortium 0.593225 Vaughan TL 0.552829 oesophageal adenocarcinoma 0.415979 Radiofrequency ablation 0.374836 systematic review 0.372952 estudios cohortes 0.383438 Franco E 0.368432	CLICK HERE
3670	National Cancer Institute	Html	es	Estudio TAILORx indica que mujeres con riesgo bajo de recurrencia de cáncer de seno pueden abstenerse de quimioterapia	Resumen de resultados del estudio TAILORx indica que mujeres con cáncer de seno receptor de hormonas en estadio inicial tienen un riesgo bajo de recurrencia según una prueba de expresión de 21 genes.	Assigning Individualized Options 0.731016 NIC-Clinical Trials Group 0.677172 Therapy Evaluation Program 0.674291 quimioterapia adyuvante mejora 0.979078 doctor joseph sparano 0.667749 doctora jo anne 0.660047 llamada puntuación 0.615517 Estados Unidos 0.857653 NRG Oncology 0.56481	excelentes resultados 0.548811 cuáles mujeres 0.873744 Oncotype DX® 0.57646 invasivo enfermedad 0.55814 New England Journal 0.693093 Clinical Oncology 0.572538 Nueva Zelanda 0.530968 estudio tailorx 0.733998	CLICK HERE
3851	National Cancer Institute	Html	en	Treating Cancer without Harming the Heart	Researchers from the fields of oncology and cardiology are working to find ways to prevent, manage, and possibly even reverse the cardiovascular side effects of certain cancer therapies.	childhood cancers 0.722954 cardiovascular changes 0.633513 cancer treatment-related cardiotoxicity 0.773654 ischemic heart disease 0.641571 research 0.740587 task force 0.629922 childhood cancer increases 0.668587 cardiac health 0.652664 heart problems 0.663961 heart failure 0.684862 risk factors 0.812151 certain cardiac functions 0.66508 Community Oncology Research 0.635145 ischemic cardiac disease 0.673041 breast cancer patients 0.750275 adult survivors 0.677672 heart 0.763054 breast cancer trial 0.667286 Prevention Trials Research 0.631942 radiation therapy 0.716677 childhood cancer 0.74187 cancer treatments 0.731665 childhood cancer treatments 0.686861 study 0.637136	community oncology 0.686779 cancer treatment—chemotherapy agents 0.673113 cardiac side effects 0.698632 Anderson Cancer Center 0.750363 early cardiac dysfunction 0.678902 new research strategies 0.65852 trastuzumab-related cardiac events 0.724465 Dana-Farber Cancer Institute 0.652906 Community Oncology Cardiotoxicity 0.640076 cardiac risk factors 0.767014 subsequent research agendas 0.636051 cardiac adverse effects 0.710556 MD Anderson Cancer 0.75179 cardiac arrhythmia 0.64223 NCI Community Oncology 0.685131 NCI-supported cardiotoxicity studies 0.649029 breast cancer 0.957268 treatment-induced cardiac disease 0.677462 NCI community-based oncology 0.638369 breast cancer treatments 0.671567 Vanderbilt-Ingram Cancer Center 0.655353 cancer clinical trials 0.814235 underlying cardiovascular risk 0.658241 cardiovascular problems 0.640023	CLICK HERE
16838	National Cancer Institute	Html	en	University of Texas — Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology	The focus of the University of Texas MD Anderson Cancer Nanotechnology Training Center is presented here.	unique boot camp 0.665183 lab management skills 0.648892 Rice University 0.515834 M.D. 0.338543 Objectives 0.334693 MD Anderson 0.892403 preparation 0.332958 independent careers 0.500052 problem 0.335383 MD Anderson CNTC 0.66004 Ph.D. 0.338612 seminar experiences 0.507875 translational research 0.966631 academic labs 0.516268 hands-on coursework 0.547621 project management 0.489839 Konstantin Sokolov 0.587384 future leaders 0.517794 independent research project 0.702082 Texas 0.33468 cancer nanotechnology 0.891595 translational research projects 0.795763 training program 0.532137 multidisciplinary mentorship 0.538033 post-doctoral training 0.533942	trainees 0.545607 specific interests 0.517161 Rebecca 0.339233 research fellowship grant 0.692269 multidisciplinary field 0.50801 Ph.D 0.333304 cancer translational research 0.824834 Cancer Management 0.515303 gap 0.336671 Principal Investigator 0.540969 Didactic coursework 0.550767 completion 0.335106 Center 0.334629 MD Anderson Cancer 0.714625 NCI Nanotechnology Characterization 0.789772 program faculty mentors 0.704052 current opportunities 0.49661 federal resources 0.494134 new discoveries 0.52212 Sunil Krishnan 0.581597 deep understanding 0.497785 barriers 0.38628 introductory course 0.486248 Training Focus 0.539936	CLICK HERE
16854	National Cancer Institute	Html	null	Step 4: NCI Funding Determinations	Funding determinations are made around Oct. 1 each federal fiscal year. These decisions take into account several factors, including Congressional mandates, new scientific opportunities and program priorities when deciding which grants receive funding.			CLICK HERE
17278	National Cancer Institute	Html	es	Preparación para cuidar a un enfermo con cancer	Cuidar a alguien con cáncer avanzado trae desafíos y preocupaciones nuevas. Las personas que cuidan a pacientes deben estar al tanto de muchas cosas y planificar el cuidado de su ser querido.	dándoles oportunidad 0.826428 !No hables así¡ 0.973126 Nueva York 0.867641 principales formas 0.895606 Oxford University 0.86575	Lynna J 0.87542 busque consejo 0.895137 mejores tratamientos 0.878203 surgen preguntas 0.922072	CLICK HERE